Qingchun Wang

Dr. Qingchun Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YYYa-Nan Yang
Ya-Nan Yang
QWQingchun Wang
Qingchun Wang
WXWenyi Xu
Wenyi Xu
JYJiaqi Yu
Jiaqi Yu
HZHuricha Zhang
Huricha Zhang
LSLinghui Sheng
Linghui Sheng
Berberine (BBR) is an effective cholesterol-lowering drug. Although gut microbiota has been implicated in the pharmacological activities of BBR, little evidence exists on the specific species of gut microbiota involved in its therapeutic effects, nor on linking gut bacteria to its recognized hypercholesterolemia-alleviating mechanism-upregulation of the low-density lipoprotein receptor (LDLR) in the liver. The present study was performed to identify the specific species of gut microbiota involved in the anti-hyperlipdemic effect of BBR, and interpret its mechanism through linking the gut microbiota and LDLR. The BBR-enriched gut bacterial species were identified by whole genome shotgun sequencing. Pure cultured B. producta was orally administered to C57BL/6 mice to evaluate its anti-hyperlipdemic effect. The LDLR-upregulating effect of B. producta was evaluated both in vitro and in vivo. Orally administration of BBR (200 mg/kg) decreased serum and liver lipid levels in HFD-induced hyperlipidemic mice. Microbiome analysis indicated that Blautia was closely associated with BBR's lipid-modulating activities. Further analysis revealed that BBR selectively promoted the growth of Blautia producta. Orally treatment of HFD mice with live B. producta reduced obesity and alleviated hyperlipidemia. Notably, the B. producta significantly increased LDLR expression in the liver, and its spent culture supernatant upregulated the LDLR level and promoted LDL uptake by HepG2 cells. Simultaneously, B. producta also linked butyrate-producing and bile salt hydrolase (BSH)-inhibiting effect of BBR. The gut microbiota, especially B. producta, may confers the hypercholesterolemia-alleviating effects of berberine. B. producta represents a novel probiotic that may be used for the treatment of dyslipidemia.

9 August 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JHJiahui Han
Jiahui Han
QWQingchun Wang
Qingchun Wang

27 November 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JHJiahui Han
Jiahui Han
RLRuizhen Li
Ruizhen Li
HBHuhemuren Bao
Huhemuren Bao
YXYingchun Xi
Yingchun Xi
HLHui Liang
Hui Liang
QWQingchun Wang
Qingchun Wang

Verified
Journal Article
Open access
PDF file
YYYi Ying
Yi Ying
AMAng Ma
Ang Ma
SZShujie Zhang
Shujie Zhang
文邱文凤 邱
文凤 邱
HXHongda Xuan
Hongda Xuan
HLHaining Lyu
Haining Lyu
Chicory (Cichorium intybus L.) is a widely used nutritional and medicinal plant, whose roots are an important commercial source of inulin, while the aerial parts are often discarded during industrial processing. This study systematically compared chicory polysaccharides (CPs) extracted from aerial parts (CP-A) and roots (CP-R) with respect to their compositional features and cytoprotective effects in an oxygen–glucose deprivation/reperfusion (OGD/R)-induced H9c2 cell injury model. CP-A and CP-R differed in molecular weight distribution and monosaccharide composition, with CP-R exhibiting a higher molecular weight and fructose content. Despite these differences, both fractions significantly improved cell viability and reduced oxidative and biochemical injury markers. Integrated proteomic and transcriptomic analyses indicated that CP-A and CP-R were associated with the modulation of stress-responsive signaling networks, prominently involving oxidative stress-linked MAPK/NF-κB pathways. These findings demonstrate comparable cytoprotective activities of polysaccharide-rich fractions from roots and aerial parts and support the valorization of chicory aerial biomass as a potential source of functional ingredients for cardiovascular health.

13 February 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YXYuru Xu
Yuru Xu
YCYing Cao
Ying Cao
LZLinen Zou
Linen Zou
WUWulanna
Wulanna
XLXinyu Liu
Xinyu Liu
LSLinghui Sheng
Linghui Sheng
Objective: To elucidate the protective effects of aqueous Coriandrum sativum seed extract against high-fat, high-sugar diet (HSFD)-induced glucolipid metabolic disorder in mice, with particular focus on gut–liver axis regulation involving hepatic metabolism, oxidative stress, inflammation, and gut microbiota composition. Methods: Male mice were fed an HSFD and orally treated with Coriandrum sativum seed extract (1.0 or 2.0 g/kg/day) for eight weeks. Biochemical parameters, histopathology, hepatic gene expression, oxidative stress markers, and gut microbial profiles were assessed via standard assays, RT-qPCR, Western blot, histological staining, and full-length 16S rRNA gene sequencing with functional prediction. Results: The extract significantly ameliorated HSFD-induced metabolic impairments, including hyperglycemia, hyperlipidemia, insulin resistance, and hepatic steatosis. Histological improvements were observed in the liver, pancreas, and colon. Hepatic expression of FAS, NF-κB, and IL-6 was suppressed, while PPARα and LDLR expression was restored. Antioxidant defenses were enhanced by reducing malondialdehyde and increasing superoxide dismutase activity. Microbiota analysis revealed partial restoration of beneficial taxa such as Lactobacillus murinus and Lachnospiraceae _UCG-006, alongside enrichment of microbial pathways related to energy and carbohydrate metabolism. Conclusion: Aqueous Coriandrum sativum seed extract exerts systemic metabolic benefits in diet-induced glucolipid dysregulation by targeting the gut–liver axis. Its multi-targeted actions on hepatic metabolism, inflammatory signaling, oxidative balance, and gut microbiota composition support its potential as a natural therapeutic agent for metabolic disorders.